Alexion’s rehearing requests against Amgen and Samsung Bioepis rejected by UPC
MLex Summary: Two rehearing applications by Alexion Pharmaceuticals regarding decisions in separate cases against Amgen and Samsung Bioepis NL involving European patent 3,167,888 have been rejected the Court of Appeal of the...To view the full article, register now.
Already a subscriber? Click here to view full article